Cancer and bone fractures in observational follow-up of the RECORD study

Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials

(2013) Matteo Monami et al.   ACTA DIABETOLOGICA

Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis

(2013) C. Bosetti et al.   ONCOLOGIST

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer

(2011) X. He et al.   ANNALS OF ONCOLOGY

Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways

(2011) Besstina E. Lyles et al.   CELL CYCLE

Diabetes and Cancer: A Consensus Report

(2010) E. Giovannucci et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials

(2010) P. D. Home et al.   DIABETOLOGIA

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

(2009) John Dormandy et al.   DRUG SAFETY

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Clinical Use of PPARγLigands in Cancer

(2008) Jennifer L. Hatton et al.   PPAR Research